This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Delcath: Safety Questions Behind FDA Delay

Once Delcath resubmits its chemosaturation system for FDA approval, the agency will first decide if the bolstered application is acceptable for review, then regulators will begin the process of formally weighing the efficacy and safety data in order to make an approval decision. A September resubmission could lead to a March 2012 FDA approval decision.ΓΈ

Data from the phase III study were presented last June at the American Society of Clinical Oncology (ASCO) annual meeting. In that study, 61% of patients treated with melphalan via the chemosaturation system reported moderate to severe neutropenia, a condition of abnormally low white blood cells that can lead to serious infections.

Another 74% of Delcath-treated patients in the phase III study reported moderate to severe thrombocytopenia, or an abnormally low level of platelets that can result in bleeding.

The mortality rate in the phase III study attributed to treatment with Delcath's system was 7.5%. Two patients died due to neutropenic sepsis while a third patient died from liver failure, according to the ASCO data presentation.

When these safety data were presented last June, concerns were raised that perhaps the high dosages of melphalan used were leaking out of the liver and causing severe side effects and toxicity in patients. Hobbs disputes that concern, insisting Tuesday that the safety profile of melphalan as used in the chemosaturation procedure is "identical" to the safety of melphalan already approved today.

Delcath conducted the phase III study of the chemosaturation system under a Special Protocol Agreement with the FDA. Regulators have not questioned or challenged the conduct of the study, Hobbs said.

Melanoma patients with cancer in the liver treated with Delcath's system went a median of 245 days without progression of those liver tumors compared to 49 days without progression for patients treated with best alternative care. Those data satisfied the study's primary endpoint with statistical significance but a key secondary endpoint of the study -- an improvement in overall survival -- was not met.

The lack of a survival benefit demonstrated by Delcath's chemosaturation system was a point of criticism by a researcher who critiqued the phase III data at last June's ASCO meeting.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,919.59 +80.85 0.48%
S&P 500 1,981.60 +9.86 0.50%
NASDAQ 4,527.5140 +19.2020 0.43%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs